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Introduction
Heightened de novo lipogenesis is a hallmark of human malignancies including ovarian cancer. The current ovarian cancer pilot research project titled "Pro-lipogenic action of lysophosphatidic acid in ovarian cancer" is to determine the role of endogenous lysophosphatidic acid (LPA) in lipogenesis and metabolic abnormalities of ovarian cancer cells. The scopes of research are Task 1: To define the role of endogenous LPA in regulation of lipogenesis in ovarian cancer cells; and Task 2: To determine the contribution of LPA-driven lipogenesis to metabolic abnormalities of ovarian cancer cells We have pursued these specific tasks as detailed below. Fig. 1 ), suggesting that LPA is a major constituent of serum to promote lipogenesis in cancer cells. We are currently testing the effects of several LPA-inducing agents such as TPA and EGF (1).
Body of Research

1.2
Assessment of the effects of manipulating LPA-producing enzyme autotaxin (2) on activation of lipogenic pathways and de novo lipid synthesis in ovarian cancer cells Two approaches have been utilized to address the role of autotaxin in activation of lipogenic pathways and de novo lipid synthesis in ovarian cancer cells. First, autotaxin was overexpressed in ovarian cancer cell lines. High levels of autotaxin protein were detectable in stable clones (data not shown). Second, we used autotaxin recombinant protein that we prepared previously. The recombinant protein was made in mammalian cells and of sufficient purity and activity as we described (3) . We are currently testing appropriate doses and kinetics for further analysis in ovarian cancer cell lines.
1.3
Assessment of the effects on lipogenic enzymes and lipogenesis of pharmacological and molecular inhibition of iPLA2, another enzyme involved in LPA production in ovarian cancer cells iPLA2b is a potential enzyme involved in generation of endogenous LPA (4, 5) . We generated stable clones to overexpress dominant negative form of iPLA2b (Fig. 2) . Preliminary data indicate that ovarian cancer cell clones expressing the dominant negative iPLA2b were activity and growth inhibited (Fig.  2) . However, it remains to be determined in the next few months if this is associated with inhibition of lipogenesis.
Aim 2. To determine the contribution of LPA-driven lipogenesis to metabolic abnormalities of ovarian cancer cells:
2.1 Analysis of the effects of LPA and LPA production on mitochondrial respiration in ovarian cancer cells To this end, we proposed to analyze both cellular ATP levels and mitochondrial ATP production/oxygen consumption in ovarian cancer cells. This task relies on the development of the techniques. We have so far focused on the first part to analyze the effect of LPA on the total cellular ATP and AMP/ATP ratio, which could provide explanation on how LPA inactivates AMPK and activates ACC in ovarian cancer cells (see the attached manuscript Fig. 3 ). We initially tried the luciferin/luciferase method to measure ATP. Although straightforward and reportedly to be quantitative (6), we found that the approach was largely qualitative with huge variations from experiment to experiment (data not shown). We thus switched to an HPLC-based assay which was more accurate and reproducible. As shown in Fig. 3 , treatment of ovarian cancer cell line with LPA increased ATP production and decreased AMP/ATP ratio, a prominent regulator of the AMPK activity in mammalian cells.
2.2
Elucidation of the role of LPA and LPA production in regulation of lipid catabolic enzymes including monoacylglycerol lipase (MAGL) (7) and fatty acid beta oxidation (8) When they were treated with LPA to stimulate their proliferation, ovarian cancer cells were incubated with serum and lipid-free medium. An interesting question is whether the pro-lipogenic action of LPA is due to the lack of lipids in the extracellular environment. In other words, if provided with fatty acids, are ovarian cancer cells still stimulated by LPA to undergo active lipogenesis? To answer this, we have examined the effects of LPA in the presence of extracellular palmitate. Palmitate only slightly reduced LPA-dependent lipogenesis. The result has been published in the attached manuscript (Fig. 4A ). In addition, we have also examined whether supply of fatty acids could potentiate LPA-induced cell growth. The data shown in Fig. 4 indicate that the presence of palmitate enhanced the growth-promoting activity of LPA in ovarian cancer cells. Since environmental fatty acids do not influence fatty acid synthesis, its effect on cell growth is most likely mediated by its catabolism through b-oxidation. We will further confirm this by examining b oxidation directly and the enzymes involved in fatty acid release.
2.3
Determination of the effects of LPA signaling on cholesterol synthesis and structures and functions of lipid rafts We have examined the effects of LPA on the rate-limiting enzyme of cholesterol synthesis HMG-CoA reductase and on the cellular cholesterol levels. LPA stimulates HMG-CoA expression in ovarian cancer cells. The result is now published in Fig. 2B of the attached manuscript. LPA also stimulated production of cellular cholesterol (data not shown), consistent with the activation of HMG-CoA expression by LPA. We are currently isolating detergent soluble and resistant fractions from control and LPA-treated cells to determine if LPA alters structure and functions of lipid rafts as well as localizations of lipid raft-associated proteins.
2.4
Metabolic profiling of alterations in membrane and cellular lipids modulated by LPA using mass spectrometry This will be major task for the 2 nd year of the project. One graduate student in the lab is currently receiving technical training in the VCU mass spectrometry core. 
Key Research Accomplishments
Conclusions
During the first year of the funding support, we have pursued the specific aims and subaims as planned. The major results are summarized in key research accomplishments. Some of these results have been published in our recent paper attached. We have also developed necessary reagents or learnt important techniques in preparation for the remainder of the project as detailed under each specific aims. We expect to accomplish the project objectives within the 2 nd year of the support with no major difficulty or change in research directions. One of the most common molecular changes in tumor cells is the heightened rate of de novo lipid synthesis compared with their normal counterparts. The aberrant lipogenesis in cancer cells is mediated by increased expression and activity of key lipogenic enzymes, primarily fatty acid synthase (FAS) 2 and acetyl-CoA carboxylase (ACC). Interestingly, the alterations in these key lipogenic enzymes are critical for the development and maintenance of the malignant phenotype (1) . It occurs at early stages of tumorigenesis and becomes more pronounced in advanced cancers (1, 2) . Overexpression of FAS correlates with poor prognosis in several types of human malignancies, including ovarian cancer (3, 4) . Furthermore, tumor cells depend heavily on or are "addicted" to de novo lipid synthesis to meet their energetic and biosynthetic needs, irrespective of the nutritional supplies in the circulation (1). Consistent with this, pharmaceutical inhibitors of FAS suppress tumor cell proliferation and survival and enhance cytotoxic killing by therapeutic agents (5-10). However, one barrier to cancer patient applications of these inhibitors is their nonselective suppression of fatty acid synthesis in both normal and malignant tissues, which could deteriorate weight loss, anorexia, fatigue, and other cancer-associated complications. To target lipid anabolism in tumors specifically, it is important to identify the mechanism for the hyperactive lipogenesis in cancer cells, which is, however, poorly understood.
Lysophosphatidic acid (LPA), the simplest phospholipid, has long been known as a mediator of oncogenesis (11) . LPA is present at high levels in ascites of ovarian cancer patients and other malignant effusions (11) (12) (13) . LPA is a ligand of at least six G protein-coupled receptors (14) . The LPA 1 /Edg2, LPA 2 /Edg4, and LPA 3 /Edg7 receptors are members of the endothelial differentiation gene (Edg) family, sharing 46 -50% amino acid sequence identity (14) . GPR23/P2Y9/LPA 4 of the purinergic receptor family, and the related GPR92/LPA 5 and P2Y5/LPA 6 have been identified as additional LPA receptors, which are structurally distant from the LPA 1-3 receptors (14, 15) . The Edg LPA receptors, in particular LPA 2 , is overexpressed in many types of human malignancies, including ovarian cancer (11, 16) . Strong evidence implicates LPA 2 in the pathogenesis of ovar-* This work was supported, in whole or in part, by National Institutes of Health Grants 2R01CA102196 and R21CA161478 from NCI (to X. F.). This work was also supported by Department of Defense Ovarian Cancer Research Program Grant W81XWH-11-1-0541 (to X. F.) and The Jeffress Memorial Fund award (to X. F.). 1 To whom correspondence should be addressed. Tel.: 804-8280787; Fax:
804-828-1473; E-mail: xfang@vcu.edu.
ian, breast, and intestine tumors (16 -18) , although the exact oncogenic processes involved remain elusive. In this study, we observed that LPA stimulated proteolytic activation of two isoforms of the sterol regulatory elementbinding proteins (SREBPs), transcription factors involved in regulation of FAS and other lipogenic enzymes for biosynthesis of fatty acid and cholesterol. In addition, LPA induces dephosphorylation of AMPK␣ at Thr-172 and concomitant dephosphorylation of ACC at Ser-79. The dephosphorylation of ACC at Ser-79 is associated with activation of the enzyme (19) . These LPA-induced changes in the lipogenic enzymes occurred hours after exposure to LPA, and the effects were sustained for many hours. Consistent with LPA activating these lipogenic pathways, LPA increased de novo lipid synthesis. We identified LPA 2 , the receptor subtype overexpressed in ovarian cancer and other human malignancies, as the key receptor responsible for delivery of the lipogenic effect of LPA. The intracellular G 12/13 -Rho signaling cascade is critical for LPA activation of the SREBP, whereas G q -PLC is involved in LPA-mediated dephosphorylation and inhibition of AMPK. These findings reveal a novel mode of the cancer cell-specific regulation of lipogenesis by an intercellular factor present in the circulation and tumor microenvironments.
EXPERIMENTAL PROCEDURES
Reagents-LPA (1-oleolyl, 18:1) was obtained from Avanti Polar Lipids, Inc. (Alabaster, AL). Prior to use, LPA was dissolved in PBS containing 0.5% fatty acid-free bovine serum albumin (BSA) purchased from Roche Applied Science. Acetic acid (1-14 C) was obtained from Moravek Biochemicals (Brea, CA). Plasmid DNA was purified using the endo-free purification kit from Qiagen (Valencia, CA). The transfection reagent Dharmafect 1 was obtained from Dharmacon, Inc. (Lafayette, CO), and TransIT-TKO was obtained from Mirus Bio (Madison, WI). Luciferase assay reagents were obtained from Promega (Madison, WI). Anti-SREBP-1 and anti-SREBP-2 antibodies were obtained from BD Biosciences. Anti-phospho-AMPK␣ (Thr-172), anti-AMPK␣, anti-phospho-ACC (Ser-79), anti-ACC, and anti-FAS antibodies were obtained from Cell Signaling (Danvers, MA). Anti-tubulin antibody was obtained from EMD4Biosciences (Gibbstown, NJ). BODIPY 493/503 and cell culture reagents were purchased from Invitrogen. The TaqMan Universal PCR Master Mix and qPCR probes for LPA 1 , LPA 2 , LPA 3 , 3-hydroxy-3-methylglutaryl-CoA (HGMCoA) reductase, and GAPDH were obtained from Applied Biosystems (Carlsbad, CA). Calpain I inhibitor, water-soluble cholesterol, the FAS inhibitor C75, the ACC inhibitor TOFA, and sodium palmitate were purchased from Sigma.
Cell Culture-The sources of ovarian cancer cell lines used in the study were described previously (20) . These cells were cultured in RPMI medium supplemented with 10% FBS, 100 units/ml penicillin, and 100 g/ml streptomycin. IOSE-29 was originally obtained from Dr. N. Auersperg (University of British Columbia, Canada) and cultured as described previously (21) .
siRNA, Plasmids, and Transfection-The siRNA oligos for LPA 1 , LPA 2 , LPA 3 , and FAS were obtained from Applied Biosystems. These siRNAs were transfected into cells using Dharmafect 1 following the manufacturer's protocol. In brief, cells were plated in 6-well plates to reach 50 -60% confluence before transfection. Cells were then transfected with target-specific siRNA or nontargeting control siRNA (150 pM) with Dharmafect 1 (4 l) for 12-16 h. Approximately 48 h post-transfection, the cells were serum-starved overnight before LPA treatment. Lentiviruses carrying short hairpin RNA (shRNA) for LPA [1] [2] [3] receptors were kind gifts from Dr. S. Huang (Medical College of Georgia) (22) . The expression vector pcDNA3 expressing the dominant negative form of G i was provided by Dr. P. Hylemon (Virginia Commonwealth University) (23, 24) . The G q and G 12 cDNAs were provided by Dr. R. D. Ye (University of Illinois at Chicago). The dominant negative mutants of G q (G208A) and G 12 (G228A) (25) (26) (27) in pcDNA3 were made using the QuikChange XL site-directed mutagenesis kit (Stratagene, Santa Clara, CA). The plasmids and the vectors expressing N19Rho and botulinum toxin C3 were described previously (28, 29) . These plasmids were transfected into ovarian cancer cell lines using Lipofectamine LTX Plus (Invitrogen) following the manufacturer's instruction.
Luciferase Assays-The SREBP-responsive luciferase reporter vector (pGL2-3ϫSREBP-TK-Luc) was generated by cloning three repeats of the SREBP consensus sequence (AAAATCACCCCACTGCAAACTCCTCCCCCTGC) (30, 31) into the NheI and HindIII sites in front of the herpes simplex virus thymidine kinase gene promoter (Ϫ35 to ϩ50) in the pGL2-TK-Luc vector (32) . Ovarian cancer cell lines were transfected with the luciferase vector using TransIT-TKO according to the manufacturer's protocol. About 48 h after transfection, the cells were starved overnight and treated with LPA or vehicle (BSA) for 12 h. Cell extracts were prepared and assayed for luciferase activity using the luciferase assay kits from Promega.
Western Blotting-Cells were lysed as described previously (33) . Total cellular proteins were resolved by SDS-PAGE, transferred to immunoblot membrane (polyvinylidene difluoride) (Bio-Rad), and immunoblotted with antibodies following the protocols of the manufacturers. Immunocomplexes were visualized with an enhanced chemiluminescence detection kit from Amersham Biosciences.
Quantitative PCR (qPCR)-Total cellular RNA was isolated from cultured cells using TRIzol (Invitrogen). Complementary DNA (cDNA) was synthesized using the High-Capacity cDNA reverse transcription kit (Applied Biosystems). The relative levels of LPA 1 , LPA 2 , LPA 3 , HMG-CoA reductase, and GAPDH were determined by qPCR using gene-specific probes, the TaqMan Universal PCR master mix, and the Applied Biosystems 7900HT real time PCR system. Measurement of de Novo Lipid Synthesis-Cells were grown in 6-well plates and serum-starved prior to treatment with LPA or vehicle for 24 h. The cells were labeled with [
14 C]acetic acid (5 Ci/ml) for the last 6 h of incubation. The cells were then washed twice with PBS and lysed with lysis buffer (25 mM HEPES, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 0.2 mM EDTA, 0.5% sodium deoxycholate, 20 mM glycerophosphate, 1 mM sodium vanadate, 1 mM PMSF, 10 g/ml leupeptin, and 10 g/ml aprotinin). Lipids were extracted using a chloroform/ methanol solution (2:1). Phase separation was achieved by centrifugation at 3200 ϫ g for 10 min. The organic phase was extracted and dried with a speed vacuum. Lipids were dissolved in Ultima Gold Mixture (PerkinElmer Life Sciences) and counted using Beckman LS 6500 scintillation counter. Each measurement was performed in triplicate and normalized to cell numbers.
Lipid Staining-Cells were grown and serum-starved prior to treatment with LPA or vehicle for 24 h. Cells were then stained with BODIPY 493/503 at a final concentration of 0.5 g/ml in PBS at 37°C for 30 min, followed by counter-staining with Hoechst (10 g/ml) for 15 min. Cells were then fixed with 2% paraformaldehyde and visualized with fluorescence microscopy.
Quantification of Triacylglycerols (TAG) and Phospholipids-TAG and phospholipids were extracted and quantified with the EnzyChrom triglyceride assay kit and the EnzyChrom phospholipid assay kit (BioAssay Systems, Hayward, CA), respectively, according to the manufacturer.
Statistics-All numerical data were presented as means Ϯ S.D. The statistical significance of differences was analyzed using Student's t test, where p Ͻ 0.05 was considered statistically significant. In all figures, the statistical significances were indicated with an asterisk if p Ͻ 0.05 or two asterisks if p Ͻ 0.01.
RESULTS
LPA Induces Proteolytic Cleavage and Activation of SREBP in a Cholesterol-sensitive Manner-
The hyperactive lipogenesis is a hallmark of tumor cells (1, 34) . To identify pathophysiological mechanisms driving the lipogenic program in cancer cells, we examined the potential role of LPA, an endogenous regulator of many cellular functions in ovarian cancer and other human malignancies. We first assessed whether LPA was capable of activating the SREBP transcription factors that play crucial roles in regulating expression of lipogenic enzymes. Treatment of Caov-3, OVCA-432, and other ovarian cancer cell lines, including OVCAR-3, with LPA induced cleavage of the precursor forms of SREBP-1 and SREBP-2 in a time-dependent manner (Fig. 1A) . The cleaved mature forms of SREBP-1 and SREBP-2 were detectable at 4 h and peaked at 12 h post-LPA treatment. In contrast to the ovarian cancer cell lines, LPA failed to activate SREBP-1 or SREBP-2 in the immortalized ovarian surface epithelial cell line IOSE-29 (Fig. 1A) or normal ovarian epithelial cells (data not shown), suggesting a cancer cell-specific mechanism for SREBP activation by LPA in ovarian cancer cells.
In physiological conditions, SREBP-1 and SREBP-2 are regulated by the intracellular sterol content. In their precursor forms, SREBPs are attached to the endoplasmic reticulum. Specific signaling cues such as reduced cholesterol levels trigger SREBP cleavage-activating protein (SCAP)-mediated transport of SREBP from endoplasmic reticulum to Golgi, where they are cleaved by proteases S1P and S2P to release the mature/active form (35) . At high sterol concentrations, the SREBP-SCAP complex is retained in the endoplasmic reticulum due to increased binding to INSIG proteins (36) . To determine whether LPA activation of SREBP could bypass cholesterol regulation, we preloaded Caov-3 and OVCA-432 cells with cholesterol (10 g/ml) complexed with 0.1% fraction V fatty acid-free BSA in PBS, and then assessed activation of SREBP-1 in response to LPA. As shown in Fig. 1B , cholesterol treatment reduced both basal and LPA-induced active SREBP-1 levels, indicating that activation of SREBP by LPA remains sensitive to the cholesterol availability.
To determine whether LPA-induced SREBP cleavage is sufficient to activate SREBP transcriptional activity, Caov-3 and OVCA-432 cells were transfected with the SREBP-responsive reporter pGL2-3ϫSREBP-TK-Luc. As shown in Fig. 1C , treatment of transfected cells with LPA significantly enhanced luciferase activity in these cells. Similar to the SREBP cleavage, SREBP-dependent luciferase activity was also sensitive to cholesterol treatment (Fig. 1C) . 
LPA Induces Expression of SREBP Target Genes FAS, ACC, and HMG-CoA
Reductase-To substantiate the biological significance of SREBP activation by LPA, we monitored expression levels of FAS, ACC, and HMG-CoA reductase. These are well known targets of SREBP-1 and SREBP-2 involved in biosynthesis of fatty acid and cholesterol. Treatment of Caov-3, OVCA-432, and OVCAR-3 cells with LPA increased expression levels of FAS and ACC proteins as shown in Fig. 2A . The mRNA levels of these key enzymes for fatty acid synthesis (data not shown) and the rate-limiting enzyme for cholesterol synthesis HMG-CoA reductase were also significantly increased by treatment of ovarian cancer cell lines with LPA (Fig. 2B) , providing evidence that activation of SREBP-1 and SREBP-2 by LPA is sufficient to increase expression of key endogenous lipogenic enzymes in ovarian cancer cells.
LPA Induces Dephosphorylation of AMPK and ACC-In addition to transcriptional up-regulation, the activity of ACC is inhibited by AMPK-mediated phosphorylation. AMPK, a highly conserved protein serine/threonine kinase, acts as an energy sensor and regulator of cellular metabolism, shutting down energy-consuming anabolic processes and activating energy-yielding catabolic processes (37) . AMPK is activated through phosphorylation of Thr-172 within the activation domain of the ␣-subunit (38) . To determine the effect of LPA on AMPK and its downstream target ACC, we analyzed the phosphorylation status of AMPK␣ at this residue as a surrogate of activation of the enzyme. Treatment of Caov-3 and OVCA-432 cells with LPA induced late onset and sustained dephosphorylation of AMPK␣ (Fig. 3) . The decrease in AMPK␣ phosphorylation was detectable at 8 h and became prominent at 12 h. Consistent with a predominant role of AMPK␣ in phosphorylation of ACC, AMPK␣ dephosphorylation in LPAtreated cells was accompanied by a decrease in ACC phosphorylation at Ser-79 (Fig. 3) . Dephosphorylation of this site is known to enhance ACC enzymatic activity. The effects of LPA on dephosphorylation of AMPK␣ and ACC were not detected in IOSE-29 cells (data not shown). These results establish that LPA signaling is coupled to activation of ACC via inhibition of AMPK. (5, 39) . We examined whether LPA-induced activation of lipogenic enzymes is functionally sufficient to stimulate de novo lipid synthesis. The ovarian cancer cell lines Caov-3 and OVCA-432 and the immortalized IOSE-29 cells were treated with LPA or BSA as vehicle control and pulselabeled with [ 14 C]acetic acid to monitor the amount of new lipid synthesis. As demonstrated in Fig. 4A (left panel) , LPA treatment led to a significant increase in 14 C incorporation into the cellular lipid fractions, reflecting an increase in newly synthesized lipids in response to LPA. The lipogenic effect of LPA was specifically detected in multiple ovarian cancer cell lines but not in the nontransformed IOSE-29 cells, wherein LPA failed to induce SREBP activation or AMPK dephosphorylation. Because these cells were treated with LPA in serum-free medium lacking extracellular fatty acids, we wanted to determine whether the increase in lipogenesis in response to LPA is influenced by availability of extracellular lipids. As shown in Fig. 4A (right panel) , exogenously supplemented palmitate slightly reduced LPA-driven lipogenesis. The reduction was, however, statistically insignificant, indicating that the lipogenic role of LPA is largely independent of availability of extracellular fatty acids. Consistent with the pro-lipogenic action of LPA, staining with the lipophilic dye BODIPY 493/503 revealed that LPA induced moderate increases in the intracellular contents of neutral lipids in Caov-3 and OVCA-432 cells but not in IOSE-29 cells (Fig. 4B) . These results were further supported by the increases in both cellular TAG and phospholipids following LPA treatment (Fig. 4, C and D (Fig. 5A) . The other non-Edg LPA receptors are either absent or expressed inconsistently in ovarian cancer cells (40, 41) . Thus, we focused on the potential role of LPA [1] [2] [3] in the regulation of lipogenesis. We used siRNA to knock down expression of LPA 1 , LPA 2 , and LPA 3 in Caov-3 cells and examined SREBP activation and AMPK␣ dephosphorylation in response to LPA treatment. Interestingly, only knockdown of LPA 2 remarkably attenuated LPA-induced cleavage of SREBP-1, dephosphorylation of AMPK␣ at Thr-172 (Fig. 5B) , as well as expression of FAS and ACC (Fig. 5C ). There were little inhibitory effects on SREBP-1 activation, AMPK␣ dephosphorylation, and expression of FAS and ACC in conjunction with LPA 1 or LPA 3 knockdown. We encountered a technical difficulty in achieving efficient knockdown of LPA receptors with transient siRNA in OVCA-432 cells. However, similar results were obtained from OVCA-432 cells when LPA receptors were stably knocked down by lentivirus-transduced shRNA (Fig. 5, B and C) . These results support a primary role of the LPA 2 receptor in LPA-dependent activation of SREBP-1 and inhibition of AMPK␣. However, overexpression of LPA 2 in IOSE-29 cells was not sufficient to activate LPA-dependent induction of FAS and ACC (data not shown), suggesting that additional signaling player(s) present specifically in malignant cells is involved.
LPA Promotes de Novo Lipid Synthesis-Few studies have examined the role of exogenous factors in regulation of lipogenesis in cancer cells
To verify this receptor subtype-specific regulation of lipogenesis, we examined the effect of LPA 2 knockdown on LPAdriven lipogenesis. The de novo lipid synthesis in LPA receptor knockdown and control cells was assessed as described earlier.
The endogenous lipid synthesis induced by LPA was strongly attenuated by siRNA-or shRNA-mediated down-regulation of LPA 2 (Fig. 5D) . In contrast, knockdown of LPA 3 (Fig. 5D) (42) . We transfected dominant negative forms of these G proteins into highly transfectable Caov-3 cells in an effort to screen for G proteins critical for LPA-dependent SREBP-1 cleavage and AMPK␣ dephosphory- , right panel) . B, the parallel cells in 6-well plates were stained with BODIPY 493/503 fluorescent dye (0.5 g/ml) for 30 min, followed by staining with Hoechst (10 g/ml) for 15 min to monitor lipid accumulation. Shown were fluorescence microscopic photographs of IOSE-29, Caov-3, and OVCA-432 cells treated with or without LPA (ϫ80 magnification). Total TAG (C) and phospholipids (D) in control and LPA-treated Caov-3 and OVCA-432 cells were determined as described under "Experimental Procedures." The results are presented as amounts of lipids per well or normalized on cell numbers to represent amounts of lipids per million cells.
lation. As shown in Fig. 6A , expression of the dominant negative G 12 attenuated LPA-induced SREBP-1 cleavage but not LPA-induced dephosphorylation of AMPK␣. In contrast, expression of dominant negative G q inhibited AMPK␣ dephosphorylation but not SREBP-1 cleavage induced by LPA. Thus, different G protein cascades are implicated in the regulation of SREBP and AMPK by LPA. Because a prominent effector of G 12/13 is the Rho GTPase, we examined whether Rho is required for LPA activation of SREBP. As expected, expression of dominant negative Rho (N19Rho) or the botulinum toxin C3, a specific inhibitor of Rho GTPase, suppressed LPA-induced cleavage of SREBP-1 (Fig. 6B) as compared with vector-transfected cells. The results demonstrate that LPA 2 promotes SREBP activation in a Rho-dependent pathway.
To elucidate the regulatory network leading to AMPK dephosphorylation, we used pharmacological inhibitors of signaling molecules downstream of G q . As shown in Fig. 6C , the PLC inhibitor U73122 but not it's inactive analog U73433 blocked AMPK␣ dephosphorylation induced by LPA. The data support a G q -PLC-dependent mechanism to control phosphorylation and activity of AMPK␣ in LPA-treated cells.
LPA-driven Cell Proliferation Requires LPA 2 and de Novo Lipid Synthesis-LPA is a mitogen that stimulates proliferation of ovarian cancer cells (43) (44) (45) (46) . To understand the biological significance of LPA-induced lipogenesis, we examined whether the pro-lipogenic activity of LPA contributes to LPA-driven proliferation of ovarian cancer cells. C75 and TOFA are well characterized specific inhibitors of FAS and ACC, respectively (47, 48) . The presence of C75 dramatically decreased cell numbers of Caov-3 and OVCA-432 cells in serum-free medium supplemented with LPA as a growth factor (Fig. 7A) , suggesting that the blockade of de novo lipogenesis could attenuate LPAinduced cell proliferation. Similar effects were observed in the presence of the ACC inhibitor TOFA (data not shown). At the concentrations we used, C75 and TOFA did not induce significant increases in apoptosis or appreciable decreases in cell viability (data not shown), suggesting that these inhibitors mainly targeted cell proliferation rather than cell survival. We also tested if exogenously added palmitate could reverse the effect of C75 on LPA-induced cell proliferation. At 10 M, palmitate partially prevented the effect of C75 (Fig. 7B ). This ability of palmitate, however, was not seen at 20 M, suggesting possible cytotoxic effect of high concentrations of palmitate.
To obtain molecular evidence for involvement of FAS in LPA-induced cell proliferation, we used siRNA to knock down FAS expression in Caov-3 and OVCA-432 cells. Down-regulation of FAS expression indeed prevented proliferation of these cells induced by LPA (Fig. 7C) . Finally, because LPA 2 is the key receptor subtype required for LPA activation of lipogenesis, we knocked down its expression to determine whether LPA 2 is an integral component of LPA-induced cell proliferation. As shown in Fig. 7D , following down-regulation of LPA 2 , both cell lines exhibited significant decrease in growth rate when the cells were incubated in serum-free medium containing LPA. Thus LPA 2 and its associated lipogenesis-promoting activity are critical for LPA-induced cell proliferation.
DISCUSSION
The majority of the adult tissues depends on dietary fat to meet their nutritional needs. In contrast, cancer cells depend on de novo lipid synthesis for generation of fatty acids, irrespective of the available extracellular supplies. Malignant cells typically show a high rate of de novo fatty acid synthesis (49, 50) . Intracellular fatty acids in rapidly dividing cancer cells not only supply energy through ␤-oxidation but more importantly serve as precursors for biosynthesis of membrane phospholipids, signaling lipids, and secondary messengers (51) . The lipogenic phenotype of cancer cells has been primarily attributed to increased expression or aberrant activity of the major lipogenic enzymes FAS and ACC. In particular, FAS, originally recognized as a tumor-specific antigen present in serum of cancer patients (34) , is overexpressed in a variety of human malignancies. However, the cellular mechanisms by which lipogenic enzymes are up-regulated in cancer cells remain poorly understood except for a few studies suggesting that steroid hormones and Her family ligands could increase FAS expression via the PI3K or MAPK pathways (52) (53) (54) (55) .
In this study, we describe a novel LPA-mediated mechanism activating de novo lipogenesis in ovarian cancer cells. We demonstrated that treatment of ovarian cancer cell lines with LPA activates the SREBP-FAS and AMPK-ACC lipogenic cascades, culminating in increased de novo lipid synthesis. The lipogenic effect of LPA was specifically observed in cancer cells as LPA failed to induce de novo lipogenesis in nontransformed IOSE-29 cells. LPA has been long known as a mediator of ovarian cancer. It is present at high concentrations in tumor microenvironments such as ascites of ovarian cancer patients and other malignant effusions (12, 13) . This study highlights the possibility that LPA is an etiological factor in tumor microenvironments to promote lipogenesis in ovarian cancer cells, although the effect of LPA in other cancer cells remains to be determined.
A significant finding of this study is the selective role of the LPA 2 receptor in LPA activation of the lipogenic pathways and LPA-driven lipogenesis. We and others have previously shown that LPA 2 and LPA 3 are overexpressed in significant fractions of ovarian cancer and in most ovarian cancer cell lines (16, 46) . LPA 1 , which is expressed by both normal and malignant ovarian epithelial cells, is dispensable for the pro-lipogenic activity of LPA in ovarian cancer cells. It is somewhat surprising that in both Caov-3 and OVCA-432 cells, knockdown of LPA 3 slightly potentiated the lipogenic effect of LPA (Fig. 5D) . The results imply that the crosstalk among co-expressed LPA receptors is important in the control of biological outcomes of LPA. The specific role of LPA 2 in the promotion of lipogenesis in tumor cells is consistent with the increased expression of this receptor in various malignancies (16, 56 -58) . Although LPA 1 and LPA 3 have also been reported to be up-or down-regulated in some cancers, overexpression of LPA 2 is most commonly seen in almost all cancer types examined (16, 56 -58) . There is also strong evidence from xenograft mouse models and transgenic mice that LPA 2 is more oncogenic compared with LPA 1 and LPA 3 (17, 59) . The compelling evidence for the implication of LPA 2 as an oncogene stems from recent studies by Yun and co-workers (18, 60) who showed that LPA 2 -deficient mice were more resistant to intestinal tumorigenesis induced by colitis or by ApcMin mutation. However, the molecular mechanisms for the oncogenic activity of LPA 2 are not well understood. Most previous studies have been focused on the ability of LPA 2 to stimulate expression of oncogenic protein factors, including IL-6, VEGF, HIF1␣, c-Myc, cyclin D1, Krüppel-like factor 5, and Cox-2 (18, 32, 60 -63) . LPA 2 seems to be more potent than other LPA receptors in driving the transcriptional effects of LPA on these LPA target genes. This study links LPA 2 to the lipogenic phenotype of ovarian tumor cells. The role of LPA 2 in lipid metabolism provides a new avenue to explore the oncogenic role of LPA.
Different G proteins downstream of the LPA 2 receptor are involved in regulation of the SREBP-FAS and AMPK-ACC pathways in LPA-treated cells. Our results showed that SREBP cleavage/activation lies downstream of the G 12/13 -Rho pathway, and AMPK dephosphorylation/inhibition is mediated by the G q -PLC cascade. LPA stimulated cleavage of the precursor SREBP into mature and active forms in a time-dependent manner, which was accompanied by increases in SREBP-dependent transcriptional activity and up-regulation of endogenous SREBP target genes. In addition, the effect of LPA on SREBP cleavage and activation remains sensitive to cholesterol-mediated regulation, indicating the sterol-sensing machinery involved in SREBP cleavage is not disrupted by LPA. The proteolytic cleavage of SREBP is controlled by the combined action of SCAP and INSIG proteins (64) . An increase in SCAP or a decrease in INSIG proteins could lead to activation of SREBP. Because androgens and insulin have been shown to regulate expression or stability of SCAP or INSIG (65, 66) , it will be of interest to determine whether LPA modulates these proteins or their ratios to activate SREBP. This possibility is consistent with the observation that SREBP cleavage occurs hours after exposure of ovarian cancer cells to LPA.
It has yet to be determined how the G q -PLC pathway is linked to dephosphorylation and inhibition of AMPK␣. Obviously, our observation does not agree with Kim et al. (67) , who recently reported that LPA stimulated transient phosphorylation of AMPK␣ at Thr-172 within the first 10 min of LPA treatment in the SKOV-3 ovarian cancer cell line. In our experiments involving multiple ovarian cancer cell lines, there was little change in AMPK␣ phosphorylation status at the early time points. Instead, we observed a time-dependent decrease in phospho-AMPK␣ levels, which maximized after 12 h of incubation with LPA. The serine-threonine kinase LKB1, encoded by the Peutz-Jeghers syndrome tumor suppressor gene, is believed to be primary AMPK kinase as suggested by LKB1 knock-out studies (68 -70) . LKB1 possesses a nuclear localization domain and is located predominantly in the nucleus. Upon phosphorylation, LKB1 translocates to the cytoplasm where it forms an active complex with Ste20-related adaptor (STRAD) and mouse protein 25 (MO25) (71) . LPA may down-regulate LKB1 activity via modulation of its phosphorylation, nuclearcytoplasmic translocation, or association with STRAD-MO25 in the cytosol. In addition, AMPK phosphorylation could be down-regulated by inhibition of other candidate AMPK kinases such as calmodulin-dependent protein kinase kinase-␤ (71) or by activation of unknown AMPK phosphatase(s). A potential decrease in AMP/ATP ratio could also change the conformation of AMPK to prevent the active site (Thr-172) on the ␣-subunit from being exposed and phosphorylated by AMPK kinases. Fig. 1 . Knockdown of the LPA2 receptor prevents lipogenesis of ovarian cancer cells cultured in complete medium containing 10% FBS. LPA2 in OVCA-432 cells was stably knocked down by lentivirally transduced shRNA (LPA2sh). The de novo lipogenesis was quantified as described in the attached manuscript and the lipogenic activity was compared with the cells transduced with control shRNA (Csh). 
